February 26, 2002Circulation
Maximizing the Natriuretic Peptide System in Experimental Heart Failure
Why the study?
Does acute vasopeptidase inhibition combined with subcutaneous BNP improve cardiorenal hemodynamics in experimental heart failure?
Population
Anesthetized dogs with experimental congestive heart failure (CHF) produced by ventricular pacing for 10 days
Comparison
Acute vasopeptidase inhibitor omapatrilat plus… vs Acute VPI alone, acute low-dose SQ BNP alone…
Design
Preclinical
Follow-up
Acute
Authors
Discussion
Loading...
Member takes
Implication
Supports combined VPI-BNP exploration in experimental HF; hypothesis-generating for human translation.
Structured PICO
Does acute vasopeptidase inhibition combined with subcutaneous BNP improve cardiorenal hemodynamics in experimental heart failure?
P
Population
Anesthetized dogs with experimental congestive heart failure (CHF) produced by ventricular pacing for 10 days
I
Intervention
Acute vasopeptidase inhibitor (VPI) omapatrilat (1 micromol/kg IV bolus) plus low-dose subcutaneous (SQ) BNP (5 microg/kg)
C
Comparator
Acute VPI alone (omapatrilat 1 micromol/kg IV bolus), acute low-dose SQ BNP alone (5 microg/kg), and acute high-dose SQ BNP alone (25 microg/kg)
O
Outcome
Cardiorenal and humoral responses (including plasma BNP, urinary BNP excretion, urinary sodium excretion, glomerular filtration rate, cardiac output, and cardiac filling pressures)surrogate
Acute vasopeptidase inhibition potentiates the cardiorenal actions of subcutaneous BNP in experimental heart failure, suggesting a novel therapeutic strategy.
Cite This Study
Chen et al. (2002) studied this question.